ClinicalTrials.gg
RecruitingNCT07125378LIFTUpdated Jul 31, 2026

Living Independence Through Functional Training

A Phase 1/2 interventional study of Task-oriented resistance exercise in Mobility Limitation and Cognitive Impairment, sponsored by University of Florida. Recruiting at 2 sites in United States. Open to participants aged 65 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-07-31.

Sponsored by University of Florida · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
65 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 126 studies in Mobility Limitation with a site in United States — 31 open to participants now, 35 under way, 3 of them phase 3. Mobility Limitation · United States.

Planned enrollment
101st of 116
15 · median 40
Started
2026
with 9 others
Phase 1/2
2 of 126
1 open now
Primary completion
2026-11
later than 5 of 34 live
Registered
116th of 126
by date
Lead sponsor
6 of 126
University of Florida

Among the 126 studies in Mobility Limitation with a site in United States, this one is the 101st largest by planned enrollment of the 116 interventional ones that give a count, is one of 10 that started in 2026, is one of 2 in phase 1/2, reaches primary completion later than 5 of the 34 other live ones, and was the 116th registered.

Mobility Limitation

383 studies on the registry are indexed under Mobility Limitation; 106 are open to participants now.

Browse Mobility Limitation studies →

Open to participants now

31 of the 126 studies in Mobility Limitation with a site in United States are open now. Recruiting first, the newest first:

25 more — sign in →

All 31 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 65 Mobility Limitation studies recruiting now, 33 (51%) set no upper age limit and 15 (23%) stop at 75 or younger; 5 take children under 18; 9 take healthy volunteers.

This study: 65 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 126 studies in Mobility Limitation with a site in United States, or all of them as a file.
02

Study summary

The purpose of the research is to evaluate the feasibility and benefits of a six-week hybrid task-oriented resistance exercise program for older adults who have been recently discharged from home health care.

03

Conditions studied

  • Mobility Limitation
  • Cognitive Impairment

Keywords

  • Home-based intervention
  • Exercise
  • Older adults
  • Activities of daily living
  • Mobility
  • Cognition
04

Who can participate

Ages eligible
65 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • between the ages of 65 and 90 years
  • community-dwelling
  • live within a 50-mile radius of the study site with wireless connectivity in the area
  • mobility limitations as indicated by self-reported of using a mobility aid or having unsteady gait or walking slower than before
  • cognitive decline as indicated by a score \< 12 on Mini Version 2.1
  • a care partner or adult family member living in the home or nearby
  • willing to wear an activity tracker during the study period

Exclusion criteria

Exclusion Criteria:

  • plan to receive skilled rehabilitation services
  • plan to move away outside the study area in two months
  • reside in an assisted living or long-term care facility or plan to relocate to such a facility in the next three months
  • severe vision or hearing loss that impedes activity performance or communication
  • unable to stand or walk even with a mobility aid
  • unable to follow a one-step command or carry on a conversation over the phone
  • unable to commit to the six-week exercise program
  • contradictions to resistance exercise, such as the end-stage heart failure
  • a terminal disease or on hospice care
  • a neurological condition affecting motor skills
  • not able to provide consent.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    LIFT

    Participants will receive a task-oriented resistance exercise program at home.

    Behavioral: Task-oriented resistance exercise

Interventions

  • BehavioralTask-oriented resistance exercise

    The intervention program includes progressive resistance exercise and daily activity exercise, delivered over a six-week period with an ideal frequency of three sessions per week. Progressive resistance exercise will be provided through a combination of in-person and online sessions, while daily activity exercise will be delivered exclusively in person.

06

What researchers measure

Primary outcomes

  1. Short Physical Performance Battery

    The score ranges from 0 to 12, with a score of 12 indicating the best physical functioning of the lower extremity.

    Time frame: Baseline, 8 weeks, and 12 weeks.

  2. Montreal Cognitive Assessment

    The score ranges from 0 to 30, with a score of 30 indicating the best global cognitive function.

    Time frame: Baseline, 8 weeks, and 12 weeks.

Secondary outcomes

  1. Timed Up and Go Test-Single Task.

    Time in seconds to complete the test, with a longer time indicating poor functional mobility.

    Time frame: Baseline, 8 weeks, and 12 weeks.

  2. Timed Up and Go-Dual Task

    Time in seconds to complete the task, a longer time indicating the interference of the dual task effect on mobility.

    Time frame: Baseline, 8 weeks, and 12 weeks.

  3. List Sorting Working Memory Test

    The raw score ranges from 0 to 24, with a higher score indicating better working memory. The raw score is converted to a Change Sensitive Score.

    Time frame: Baseline, 8 weeks, and 12 weeks.

  4. Dimensional Change Card Sort Test

    The raw score ranges from 0 to 30, with a higher score indicating better executive function. The raw score is converted to a Change Sensitive Score.

    Time frame: Baseline, 8 weeks, 12 weeks.

  5. Flanker Inhibitory Control and Attention Test

    The raw score ranges from 0 to 30, with a higher score indicating better executive function and attention. The raw score is converted to a Change Sensitive Score.

    Time frame: Baseline, 8 weeks, and 12 weeks

  6. Pattern Comparison Processing Speed Test

    The raw score ranges from 0-133, with a higher score indicating better processing speed. The raw score is converted to a Change Sensitive Score.

    Time frame: Baseline, 8 weeks, and 12 weeks

  7. Speeded Matching Test

    The score ranges from 0 to 130, with a higher score indicating better speed of processing. The raw score is converted to a Change Sensitive Score.

    Time frame: Baseline, 8 weeks, 12 weeks

  8. Oral Symbol Digit Test

    The raw score ranges from 0 to 143, with a higher score indicating better processing speed. The raw score is converted to a Rasch score.

    Time frame: Baseline, 8 weeks, and 12 weeks

Other outcomes

  1. Patient Health Questionnaire-9

    The score ranges from 0 to 27, with a higher score indicating a higher degree of depression.

    Time frame: Baseline, 8 weeks, 12 weeks.

  2. Pain, Enjoyment of Life and General Activity Scale

    The score ranges from 0 to 10, with a higher score indicating greater pain and interference with life by pain.

    Time frame: Baseline, 8 weeks, and 12 weeks.

  3. Activity Measure for Post-Acute Care to measure everyday activity performance

    The score ranges from 0 to 71, with a higher score indicating better mobility, daily activity function, or daily cognitive ability.

    Time frame: Baseline, 8 weeks, and 12 weeks.

  4. Step counts

    The number of step counts, a higher number indicates a higher level of physical activity.

    Time frame: From enrollment to the end of intervention at 8 weeks.

  5. Sleep efficiently

    A ratio score of total sleep time divided by total time in bed per night, ranging from 0 to 1. A higher score indicates better sleep quality.

    Time frame: From enrollment to the end of the intervention at 8 weeks.

  6. Program satisfaction

    A score ranges from 0 to 6, with a higher score indicating higher satisfaction.

    Time frame: 8 weeks

07

Study locations

1 of 2 sites recruiting
  • College of Public Health and Health Professions, University of Florida
    Gainesville, Florida 32610, United States
    Recruiting
  • University of Florida
    Gainesville, Florida 32610, United States
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: Yes — All IPD that underlie the results in a publication

Time frame: Data requests can be submitted starting 3 months after article publication, and the data will be made accessible for up to 12 months.

Access criteria: Access to trial IPD can be requested by qualified researchers engaging in independent scientific research and able to provide a research proposal and data usage agreement. Please contact the trial principal investigator.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2026 (actual). Primary completion is estimated for Nov 2026, 10 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2025
First posted
Aug 15, 2025
StartActual
Jan 6, 2026
Primary completionEst.
Nov 30, 2026
CompletionEst.
Dec 31, 2026
Last update
Jul 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07125378
Responsible party
Sponsor
First posted
Aug 15, 2025
Start date
Jan 6, 2026
Primary completion
Nov 30, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jul 31, 2026

Study contacts

Chiung-ju Liu Associate Professor, PhD
Contact
c.liu1@phhp.ufl.edu
352-273-6496
Chiung-ju Liu Associate Professor, phD
principal investigator · University of Florida

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion